UNITED STATES SECURITIES AND EXCHANGE COMMISSION June 18, 2013

ORDER GRANTING CONFIDENTIAL TREATMENT UNDER THE SECURITIES ACT OF 1933

BioSante Pharmaceuticals, Inc.,

File No. 333-185391 - CF# 29782

BioSante Pharmaceuticals, Inc., submitted an application under Rule 406 requesting an extension of a previous grant of confidential treatment for information it excluded from the Exhibits to a Form S-4 filed on December 11, 2012.

Based on representations by BioSante Pharmaceuticals, Inc., that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibit(s) will not be released to the public for the time period(s) specified:

Exhibit 10.58 through April 30, 2014 Exhibit 10.59 through May 1, 2014

For the Commission, by the Division of Corporation Finance, pursuant to delegated authority:

Elizabeth M. Murphy Secretary